Humoral response to two doses of BNT162b2 vaccination in people with HIV

Authors :: Kamille Fogh
Susanne Dam Nielsen
Dina Leth Møller
Andreas Knudsen
Line Dam Heftdal
Kasper Iversen
Peter Garred
Sebastian Rask Hamm
Kirsten Grønbæk
Cecilie Bo Hansen
Linda Hilsted
Sisse R. Ostrowski
Laura Pérez-Alós
Henning Bundgaard
Ida Jarlhelt
Jan Gerstoft
Rasmus Bo Hasselbalch
Mia Pries-Heje
Source :: Heftdal, L D, Knudsen, A D, Hamm, S R, Hansen, C B, Møller, D L, Pries-Heje, M, Fogh, K, Hasselbalch, R B, Jarlhelt, I, Pérez-Alós, L, Hilsted, L M, Ostrowski, S R, Gerstoft, J, Grønbæk, K, Bundgaard, H, Iversen, K, Garred, P & Nielsen, S D 2022, ' Humoral response to two doses of BNT162b2 vaccination in people with HIV ', Journal of Internal Medicine, vol. 291, no. 4, pp. 513-518 . https://doi.org/10.1111/joim.13419
Publication Year :: 2021
Publisher :: Wiley, 2021.
Abstract: Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and